Pliant Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Pliant Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Turnaround opportunity dependent on oncology program success, but faces execution risk and cash runway constraints. While Pliant possesses strong scientific fundamentals and promising oncology data, the discontinuation of its lead IPF program represents a major setback. The company trades significantly below cash value, signaling market skepticism despite a diversified.
What is Pliant Therapeutics, Inc.'s industry? Pliant Therapeutics, Inc. (pliantrx.com) operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics. AskCyborg classifies Pliant Therapeutics, Inc. under Clinical-Stage Biopharmaceuticals / Specialty Therapeutics in its company registry.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in int...
Cyborg Score thesis
Turnaround opportunity dependent on oncology program success, but faces execution risk and cash runway...
Read the full analyst-debate transcript →Get the Latest Pliant Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePliant Therapeutics, Inc. Overview
Pro stress-test →Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in integrin biology and TGF-β modulation to address serious conditions including idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and liver fibrosis associated with NASH.
Strategic Profile
Pro stress-test →Pliant pivoted away from its lead IPF program (bexotegrast) following disappointing Phase 2b trial results in March 2025, redirecting focus toward its oncology program with PLN-101095 showing promising antitumor activity. The company maintains a portfolio approach with multiple clinical-stage programs targeting different integrin pathways and therapeutic areas, demonstrating scientific depth in integrin modulation.
Competitive Landscape
Pro stress-test →Pliant competes in antifibrotic therapeutics against companies like Boehringer Ingelheim, Roche (Galapagos assets), and FibroGen, while the oncology pivot positions it against immuno-oncology specialists. The company differentiates through its integrin-focused platform approach, though the failure of bexotegrast dilutes confidence in the fibrotic disease strategy and forces reliance on early-stage oncology success.
Industry Context
Pliant Therapeutics, Inc. operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics.
Key facts
Founded: 2015 · Headquarters: South San Francisco, California · Market cap: $71M